Genedrive has successfully completed an oversubscribed US$10 million equity fundraise
Genedrive plc has completed an equity fundraising to support the rapid development of the Genedrive® SARS-CoV-2 assays, fund the scale-up of the Genedrive-96-SARS-CoV-2 test including build-up of inventory for an initial period, fund product development, commercialization and general corporate purposes.
Genedrive is a molecular diagnostics company developing and commercializing a low-cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The company is passionate about the opportunity to not only build a sustainable business around molecular diagnostics, but to play an important role in the diagnostic and treatment challenges presented by global health issues.
Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Genedrive plc on its oversubscribed equity fundraising.
Talk to the deal team
Related deals
Ebidco has finalized a voluntary public tender offer for the shares of Eles Semiconductor Equipment
Ebidco S.r.l. has completed a voluntary public tender offer for the shares of Eles Semiconductor Equipment S.p.A.
Learn moreInstituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Learn moreAedes has finalized a rights issue
Aedes S.p.A. has successfully finalized a rights issue to support the objectives of the group’s 2024-2028 business plan and the relaunch of its business.
Learn more